Prominent examples featuring surface modification of EVs as beneficial for delivery of therapeutic compounds include overexpression of a surface‐bound peptide recognizing specifically the tumour marker EGFR, which led to a higher level of accumulation of modified vesicles in target cells, and in addition such particles loaded with let‐7a miRNA were able to inhibit tumour growth in mice (Ohno et al., 2013). The gene discussed is EGFR; the disease is neoplasm.